Anxiety and Activity Tests –Novelty-Induced Hypophagia
Assess the anxiety-related behavior in rodents in response to administration of anxiolytic and/or anxiogenic treatment
Key Research Model Applications of Novelty-Induced Hypophagia
Prior to starting the Novelty-Induced Hypophagia (NIH) test, mice are familiarized with a highly palatable snack placed into familiar metal food cup in the home-cage. On the test day, hypophagia is assessed by transferring the mice to a novel cage that contains the metal cup with the now familiar and highly palatable snack. In turn, NIH is measured by assessing the latency to start eating the snack. Commonly used inbred strains differ tremendously in NIH (Loos et al. 2009).
Mouse Behavioral Testing Made Simple.
Explore our extensive portfolio of validated and tailored behavioral and cognitive rodent tests designed to advance your research.
Novelty-Induced Hypophagia Sample Data
Although mice are highly motivated to eat from a familiarized highly palatable snack (a few crumbs of cream cracker), the novel environment induces anxiety-related-behaviour and as such a delay in consumption of the snack.
The People Behind Your Research
Thomas Vogels, PhD, In Vivo Neurology Study Director
Leads an expert team of scientists with vast experience in our Neurology models to help you choose the right model and guide your optimal study design. We provide the solution to accelerating your drug development.
Stay Curious: More Articles to Explore
MDX Mouse Model Validation Data
This month we’re highlighting one of the most commonly used mouse models to study Duchenne Muscular Dystrophy (DMD) – the MDX mouse model B10.mdx), and explore how our advanced services can support your efficacy studies in DMD. The X-linked muscular dystrophy (MDX)...
InnoSer Announces Joint Initiative with Hasselt University/BIOMED to Support Preclinical Multiple Sclerosis Research
Researchers will benefit from InnoSer’s preclinical drug development expertise combined with Hasselt University’s foundational knowledge in Multiple Sclerosis (MS) to advance preclinical MS research. Diepenbeek, Belgium, October 16th, 2024 — InnoSer, a leading...
Introduction to InnoSer’s Preclinical Epilepsy Research CRO Platform
Preclinical epilepsy-related research with InnoSer Broadly speaking, epilepsy is a large spectrum of distinct epileptic syndromes that differ in their etiologies, mechanisms, pathophysiological processes, associated comorbidities, and response profile to available...
Phenotyping of a C3-PMP22 mouse model of CMT1A
Charcot-Marie Tooth (CMT) disease is a hereditary, demyelinating peripheral neuropathy, leading to progressive muscle atrophy, weakness and subsequent walking disabilities and sensory impairments. Charcot-Marie Tooth Type 1A (CMT1A) is the most common type of CMT,...
AAALAC Accreditation
InnoSer has earned the AAALAC accreditation, demonstrating our commitment to responsible animal care and use. AAALAC International is a nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. Our accreditation is valid for three years, incl. 2023. Read more about the AAALAC accreditation programme here.
Animal Welfare
The 3Rs impact everything from policy and regulatory change to the development and uptake of new technologies and approaches. This is why InnoSer has ongoing commitment and monitoring of these processes. The steps we practice maximize our ability to replace, reduce and refine animal involvement and facilitate our commitment to these principles when it comes to research and drug development.
info@innoserlaboratories.com